Matthew B Bevers1, Zoe Wolcott2, Søren Bache3, Christina Hansen2, Cristina Sastre2, Ravi Mylvaganam4, Matthew J Koch5, Aman B Patel5, Kirsten Møller3, W Taylor Kimberly2. 1. Divisions of Stroke, Cerebrovascular, and Critical Care Neurology, Brigham and Women's Hospital, Boston, MA. 2. Division of Neurocritical Care, Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA. 3. Department of Neuroanesthesiology, Rigshospitalet, Copenhagen, Denmark. 4. Department of Pathology, Massachusetts General Hospital, Boston, MA. 5. Department of Neurosurgery, Massachusetts General Hospital, Boston, MA.
Abstract
OBJECTIVE: To investigate whether soluble growth stimulation expressed gene 2 (sST2), a prognostic marker in cardiovascular and inflammatory disorders, is associated with neurological injury after aneurysmal subarachnoid hemorrhage (SAH). METHODS: We studied SAH patients from 2 independent cohorts. Outcome assessments included functional status at 90 days using the modified Rankin Scale (mRS), mortality, and delayed cerebral ischemia (DCI). The relationships between sST2 plasma level and outcome measures were assessed in both cross-sectional and longitudinal analysis. Primary blood mononuclear cells from SAH patients and elective aneurysm controls were analyzed by multiparameter flow cytometry. RESULTS: In the discovery cohort, sST2 predicted 90-day mRS 3-6 (C index = 0.724, p < 0.001) and mortality in Kaplan-Meier analysis (p < 0.001). The association with functional status was independent of age, sex, World Federation of Neurosurgical Societies score, modified Fisher score, treatment modality, and cardiac comorbidities (adjusted odds ratio = 2.28, 95% confidence interval = 1.04-5.00, p = 0.039). Higher sST2 concentration was observed in those patients with DCI (90.8 vs 53.7ng/ml, p = 0.003). These associations were confirmed in a replication cohort. In patients with high sST2, flow cytometry identified decreased expression of CD14 (4.27 × 105 ± 2,950 arbitrary unit (AU) vs 5.64 × 105 ± 1,290 AU, p < 0.001), and increased expression of CD16 (39,960 ± 272 AU vs 34,869 ± 183 AU, p < 0.001). INTERPRETATION: Plasma sST2 predicts DCI, functional outcome, and mortality after SAH, independent of clinical and radiographic markers. Elevated sST2 is also associated with changes in CD14+ CD16+ monocytes. ANN NEUROL 2019;86:384-394.
OBJECTIVE: To investigate whether soluble growth stimulation expressed gene 2 (sST2), a prognostic marker in cardiovascular and inflammatory disorders, is associated with neurological injury after aneurysmal subarachnoid hemorrhage (SAH). METHODS: We studied SAHpatients from 2 independent cohorts. Outcome assessments included functional status at 90 days using the modified Rankin Scale (mRS), mortality, and delayed cerebral ischemia (DCI). The relationships between sST2 plasma level and outcome measures were assessed in both cross-sectional and longitudinal analysis. Primary blood mononuclear cells from SAHpatients and elective aneurysm controls were analyzed by multiparameter flow cytometry. RESULTS: In the discovery cohort, sST2 predicted 90-day mRS 3-6 (C index = 0.724, p < 0.001) and mortality in Kaplan-Meier analysis (p < 0.001). The association with functional status was independent of age, sex, World Federation of Neurosurgical Societies score, modified Fisher score, treatment modality, and cardiac comorbidities (adjusted odds ratio = 2.28, 95% confidence interval = 1.04-5.00, p = 0.039). Higher sST2 concentration was observed in those patients with DCI (90.8 vs 53.7ng/ml, p = 0.003). These associations were confirmed in a replication cohort. In patients with high sST2, flow cytometry identified decreased expression of CD14 (4.27 × 105 ± 2,950 arbitrary unit (AU) vs 5.64 × 105 ± 1,290 AU, p < 0.001), and increased expression of CD16 (39,960 ± 272 AU vs 34,869 ± 183 AU, p < 0.001). INTERPRETATION: Plasma sST2 predicts DCI, functional outcome, and mortality after SAH, independent of clinical and radiographic markers. Elevated sST2 is also associated with changes in CD14+ CD16+ monocytes. ANN NEUROL 2019;86:384-394.
Authors: Jennifer A Frontera; Jan Claassen; J Michael Schmidt; Katja E Wartenberg; Richard Temes; E Sander Connolly; R Loch MacDonald; Stephan A Mayer Journal: Neurosurgery Date: 2006-07 Impact factor: 4.654
Authors: Jochen Schmitz; Alexander Owyang; Elizabeth Oldham; Yaoli Song; Erin Murphy; Terril K McClanahan; Gerard Zurawski; Mehrdad Moshrefi; Jinzhong Qin; Xiaoxia Li; Daniel M Gorman; J Fernando Bazan; Robert A Kastelein Journal: Immunity Date: 2005-11 Impact factor: 31.745
Authors: Ellen O Weinberg; Masahisa Shimpo; Shelley Hurwitz; Shin-ichi Tominaga; Jean-Lucien Rouleau; Richard T Lee Journal: Circulation Date: 2003-02-11 Impact factor: 29.690
Authors: Masahisa Shimpo; David A Morrow; Ellen O Weinberg; Marc S Sabatine; Sabina A Murphy; Elliott M Antman; Richard T Lee Journal: Circulation Date: 2004-04-26 Impact factor: 29.690
Authors: Elizabeth K Brint; Damo Xu; Haiying Liu; Aisling Dunne; Andrew N J McKenzie; Luke A J O'Neill; Foo Y Liew Journal: Nat Immunol Date: 2004-03-07 Impact factor: 25.606
Authors: Matthew J McGirt; John C Mavropoulos; Laura Y McGirt; Michael J Alexander; Allan H Friedman; Daniel T Laskowitz; John R Lynch Journal: J Neurosurg Date: 2003-06 Impact factor: 5.115
Authors: Hae Young Baang; Hsin Yi Chen; Alison L Herman; Emily J Gilmore; Lawrence J Hirsch; Kevin N Sheth; Nils H Petersen; Sahar F Zafar; Eric S Rosenthal; M Brandon Westover; Jennifer A Kim Journal: J Clin Neurophysiol Date: 2022-03-01 Impact factor: 2.590
Authors: W Taylor Kimberly; Eric S Rosenthal; India A Lissak; Sahar F Zafar; M Brandon Westover; Riana L Schleicher; Jennifer A Kim; Thabele Leslie-Mazwi; Christopher J Stapleton; Aman B Patel Journal: Stroke Date: 2020-03-11 Impact factor: 7.914
Authors: Riana L Schleicher; Matthew B Bevers; Daniel B Rubin; Matthew J Koch; Søren Bache; India A Lissak; Aman B Patel; Eric S Rosenthal; Kirsten Møller; W Taylor Kimberly Journal: Stroke Date: 2021-06-25 Impact factor: 10.170
Authors: Bernhard Wernly; Michael Lichtenauer; Richard Rezar; Vera Paar; Clemens Seelmaier; Ingrid Pretsch; Philipp Schwaiger; Kristen Kopp; Reinhard Kaufmann; Thomas K Felder; Erika Prinz; Geza Gemes; Rudin Pistulli; Uta C Hoppe Journal: Sci Rep Date: 2021-11-05 Impact factor: 4.379